Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00449-17. doi: 10.1128/AAC.00449-17. Print 2017 Jul.

Abstract

Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.

Keywords: antibiotic resistance; beta-lactamases; carbapenemase.

Publication types

  • Multicenter Study

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azabicyclo Compounds / therapeutic use*
  • Carbapenem-Resistant Enterobacteriaceae / drug effects
  • Carbapenem-Resistant Enterobacteriaceae / pathogenicity
  • Carbapenems / therapeutic use
  • Ceftazidime / therapeutic use*
  • Cephalosporins / therapeutic use
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae / pathogenicity
  • Enterobacteriaceae Infections / drug therapy
  • Hospital Mortality
  • Humans
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • beta-Lactamase Inhibitors / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Carbapenems
  • Cephalosporins
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • beta-Lactamase Inhibitors
  • Ceftazidime